Clinical trials
Lung Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting lung cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,800 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07852871Recruiting
MicroRNA test for small testicular masses
This study looks at whether a blood test for microRNAs can help decide if a small testicular mass (a lump or growth) needs surgery or can be safely watched. It aims to avoid unnecessary surgery for benign masses.
Toronto, OntarioAges 18 years+ - NCT06427460RecruitingPhase 2
Focused radiation therapy for solid tumors
This trial tests a special type of radiation that delivers a higher dose to the center of the tumor while limiting radiation to nearby healthy organs. It's for people with certain solid tumors that haven't spread widely or have only a few metastases.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05851053Recruiting
Study of heart function years after breast cancer treatment
This study checks how well your heart works long after breast cancer treatment. If you joined the earlier de BLOC-I study, you may be invited for follow-up to understand long-term heart effects.
GroningenAges Any age - NCT06081907RecruitingPhase 1/Phase 2
IBI363 for advanced solid tumors
This trial tests a new drug called IBI363 for people with advanced solid tumors, focusing on lung cancer and melanoma. It aims to see if the drug is safe and effective, especially for those whose previous treatments have stopped working.
Changsha, HunanAges 18–75 - NCT05649683Recruiting
Blood immune testing to predict melanoma response to immunotherapy
This study checks how your immune system behaves (through an immune testing process) to see if it can predict how well advanced melanoma will respond to checkpoint inhibitor treatment. It may help doctors choose the right treatment sooner, without guessing.
Nice, Alpes-maritimesAges 18 years+ - NCT07848828RecruitingPhase 4
Blood pressure and kidney study for prostate cancer treatment
This study looks at how a common prostate cancer treatment called androgen deprivation therapy (ADT) affects blood pressure and kidney function. It may help doctors understand and manage these side effects better.
Richmond, VirginiaAges 40 years+ - NCT03949231RecruitingPhase 3
Infusion immunotherapy through the liver artery for liver cancer
This trial tests a combination of immune “brakes” medicines (PD-1/PD-L1/CTLA-4) delivered through the liver’s artery, to help treat advanced liver cancer. It may help the immune system attack the cancer more effectively, especially if other local liver treatments aren’t possible or have stopped working.
Guanzhou, GuangdongAges 18–80 - NCT06008106RecruitingPhase 3
Tunlametinib pill vs chemo for advanced NRAS melanoma
This trial tests a new pill called Tunlametinib (a MEK inhibitor) compared to standard chemotherapy for people with advanced melanoma that has a specific NRAS gene change and no longer responds to immunotherapy. It aims to see if the new pill works better or is safer than chemo.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06478225Recruiting
Cell therapy for advanced pancreatic cancer
This trial tests a new cell therapy (BGT007H) for people with advanced pancreatic cancer that has not responded to earlier treatments. The goal is to see if it is safe and can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04531696Recruiting
Post-death breast tissue donation study for cancer research
This trial invites adults with certain breast cancer conditions to donate tissue after death. Researchers hope the donated samples will help better understand cancer and improve future treatments.
LeuvenAges 18 years+ - NCT06385730RecruitingPhase 2
PD-1 blocker before surgery for elderly esophageal cancer
This trial tests a drug (PD-1 blocker) given before surgery for people over 75 with esophageal cancer. The goal is to see if it helps shrink the tumor and improve outcomes.
Shanghai, Shanghai MunicipalityAges 76 years+ - NCT06321250RecruitingPhase 1
Study of a new tablet for advanced kidney cancer
This study tests a new tablet (JMKX003948) for people with advanced clear cell kidney cancer. It aims to see if the drug is safe and how well it works.
BeijingAges 18 years+ - NCT07814352RecruitingPhase 1
A study of SX-682 with proton radiation therapy for leptomeningeal disease
This trial tests a new drug (SX-682) combined with proton radiation therapy for people whose cancer has spread to the fluid around the brain and spinal cord. The goal is to see if this combination can help control the disease better. You can join if you have melanoma or non-small cell lung cancer that has spread.
Basking Ridge, New JerseyAges 18 years+ - NCT07813000Recruiting
Patient and doctor views on cell therapies for advanced cancer
This study is a survey to learn about what patients and doctors think about newer cell-based cancer treatments (like CAR-T or TIL therapy). You will answer questions about your experiences and preferences, which will help guide future research.
Hangzhou, ZhejiangAges 18 years+ - NCT06272214RecruitingPhase 2
Adjuvant radiotherapy for esophageal cancer after immunotherapy
This trial tests if adding radiation therapy after surgery improves outcomes for people with esophageal squamous cell cancer who received immunotherapy and chemotherapy before surgery but did not achieve a complete response. It aims to see if this approach can lower the chance of the cancer coming back.
Hangzhou, ZhejiangAges 18–75 - NCT07804186RecruitingPhase 3
Adjuvant therapy for high-risk uveal melanoma
This trial is testing a combination of two oral medications (darovasertib and crizotinib) after standard local treatment for high-risk uveal melanoma that has not spread. The goal is to see if this treatment can reduce the risk of the cancer coming back.
Scottsdale, ArizonaAges 18 years+ - NCT07807163RecruitingPhase 2
Study of ficerafusp alfa with pembrolizumab for head and neck cancer
This study tests a new drug called ficerafusp alfa combined with pembrolizumab (an immunotherapy) in people with head and neck cancer that has returned or spread. The drug targets a protein that may help the immune system fight the cancer. The study is comparing two different schedules of giving the drug to see which is better.
Fort Myers, FloridaAges 18 years+ - NCT07800936RecruitingPhase 1
Injecting drug HP007 for advanced solid tumors that stopped responding to treatment
This trial tests an injected drug directly into tumors for people with advanced solid tumors like breast, head and neck, melanoma, prostate, or liver cancer that have not responded to standard treatments. It may help shrink tumors or slow their growth.
Changchun, JilinAges 18–75 - NCT07801287RecruitingPhase 2
Combination treatment before and after surgery for intermediate-stage liver cancer
This trial tests a combination of immunotherapy drugs, radiation therapy, and a targeted therapy drug before and after surgery for people with intermediate-stage liver cancer that can be surgically removed. The goal is to see if this approach can shrink tumors and improve outcomes.
TianjinAges 18 years+ - NCT06507683Recruiting
Radiation plus ripretinib for advanced GIST
This trial tests whether adding radiation therapy to the drug ripretinib can help people with advanced gastrointestinal stromal tumors (GIST) that can't be removed by surgery and have stopped responding to other treatments. It aims to see if this combination is safe and effective.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT07793695RecruitingPhase 2
Zinc plus immune therapy for advanced liver cancer
This study tests whether adding zinc supplements to standard targeted and immunotherapy improves outcomes for people with advanced liver cancer. Zinc may help the immune system work better against cancer cells.
Hefei, AnhuiAges 18–75 - NCT06393816RecruitingPhase 2
Durvalumab plus chemotherapy for advanced LCNEC lung cancer
This trial tests a combination of the immunotherapy drug durvalumab (Imfinzi) with standard chemotherapy (etoposide and a platinum drug) as a first treatment for advanced large-cell neuroendocrine carcinoma of the lung. The goal is to see if this combination works better than chemotherapy alone.
Aix-en-ProvenceAges 18 years+ - NCT05177133RecruitingPhase 2
First-line treatment for MSI-high stomach or esophagus cancer
This Phase 2 trial tests whether adding an anti–PD-1 immunotherapy (retifanlimab) and chemotherapy (capecitabine plus oxaliplatin, with leucovorin) works better for people with metastatic or inoperable stomach or gastroesophageal junction cancer that has defective mismatch repair (dMMR). If you’re eligible, it may help shrink tumors and slow the disease without needing prior chemotherapy for metastatic cancer.
AmsterdamAges 18 years+ - NCT07786766RecruitingPhase 2
Pemigatinib plus immunotherapy for FGFR2-positive bile duct cancer
This study tests a combination of two drugs—pemigatinib (a targeted therapy) and a PD-1 inhibitor (an immunotherapy)—with or without chemotherapy, for people with advanced bile duct cancer that has an FGFR2 fusion or rearrangement. The goal is to see if this combination is more effective than standard treatment, and to find better ways to treat this type of cancer.
BeijingAges 18–80
Hear when a new Lung Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,800 recruiting lung cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Liver Cancer (Locally Advanced or Metastatic)
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.